Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma

AIDS Research and Human Retroviruses

Volumn 12, Issue 8, 1996, Pages 645-649

  Patarca, Roberto ^a,b   Friedlander, Adam ^a   Harrington, William J ^a   Cabral, Lisa ^a   Byrnes, John J ^a   Fletcher, Mary Ann ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Papper Lab of Clinical Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; BLEOMYCIN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DIPEPTIDYL PEPTIDASE IV; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0029942768     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.645     Document Type: Article

References (7)

1. Gail MH, Pluda JM, Rabkin CS, Biggar RJ, Goedert JJ, Horm JW, Sondik EJ, Yarchoan R, and Broder S: Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 1991;83:695-701.
2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al.: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994;84(5):1361-1392.
3. O'Reilly SE, Hoskins P, Klimo P, and Connors JM: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991;1:17-23.
4. Fletcher MA, Azen S, Adelberg B, Gjerset G, Hassett J, Kaplan J, Niland J, Odom-Maryon T, Parker J, Stiles D, Mosley J, and the Transfusion Safety Study Group: Immunophenotyping in a multicenter study: The Transfusion Safety Experience. Clin Immunol Immunopathol 1989;52:38-47.
5. Blazquez MV, Madueno JA, Gonzalez R, Jurado R, Bachovchi WW, Pena J, and Munoz E: Selective decrease of CD26 expression in T-cells from HIV-1-infected individuals. J Immunol 1992;149(9): 3073-3077.
6. Oravecz T, Roderiquez G, Koffi J, Wang J, Ditto M, Bou-Habib DC, Lusso P, and Norcross MA: CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line. Nature Med 1995;1(9):919-926.
7. Vanham G, Kestens L, De Meester I, Vingerhoets J, Penne G, Vanhoof G, Scharpe S, Heyligen H, Busmans E, Ceupper JL, et al.: Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J AIDS 1993;6(7):749-757.